{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 450329765
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = [[Tenascin C]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7C201CLB71
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Tenatumomab''' is a [[monoclonal antibodies|monoclonal antibody]] designed for the treatment of cancer.<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], ''World Health Organization''.</ref>

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}